Loading patent…
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsYutaka Kawakami, Steven A. Rosenberg
Estimating the term…
The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.
An immunogenic peptide having contiguous amino acids derived from the MART-1 sequence (SEQ ID NO:
An immunogenic peptide having the formula X1X2X3IGILTX4 wherein:
An immunogenic peptide having contiguous amino acids derived from the gp100 sequence (SEQ ID NO. 27).
An immunogenic peptide having the a formula selected from the group consisting of X1X2X3GQYWQX4, X1X2X3QVPFSX4 and X1X2X3PGPVTX4 wherein:
Dependencies are inferred from the claim text.